Skip to content

The analgesic effect of using liposomal bupivacaine for transversus abdominis plane block after abdominal surgery : a single-center, randomized controlled clinical trial

The analgesic effect of using liposomal bupivacaine for transversus abdominis plane block after abdominal surgery : a single-center, randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114226
Enrollment
Unknown
Registered
2025-12-09
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain after abdominal surgery

Interventions

Bupivacaine Liposome Group:Bupivacaine liposome 266 mg in 40 mL of 0.9% saline, administered via subcostal TAP block and lateral TAP block, 15 mL per point, total 60 mL
Ropivacaine group:0.25% ropivacaine hydrochloride, performing subcostal TAP block and lateral TAP block, 15 mL per point, total 60 mL
Ropivacaine-Dexamethasone Combination Group:0.25% ropivacaine hydrochloride with 5mg dexamethasone, performing subcostal TAP block and lateral TAP block, 15 mL per site, total 60 mL

Sponsors

Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Subjects scheduled for abdominal surgery under general anesthesia, with an expected surgery duration of 1 to 6 hours; (2) Age >=18 years, of any gender; (3) ASA I–III; (4) No mental illness or cognitive impairment; (5) Informed of the study contents before enrollment and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Long-term use of analgesic drugs; (2) History of chronic pain or neurological disorders; (3) Severe cardiac, hepatic, renal, or respiratory dysfunction; (4) Coagulation disorders; (5) Infection at the puncture site or systemic infection; (6) Allergy to anesthetic drugs or to the study drug and its excipients, or previous severe adverse reactions; (7) Recent history of radiotherapy or chemotherapy; (8) Pregnant or breastfeeding women; (9) Participation in another clinical trial within the past 4 weeks; (10) Any unstable condition or situation that, in the investigator's judgment, could jeopardize the safety of the subject or their compliance with the study.

Design outcomes

Secondary

MeasureTime frame
Postoperative pain medication usage;Levels of pain mediators and stress hormones;Postoperative recovery condition;Occurrence of adverse reactions;Patient satisfaction;

Primary

MeasureTime frame
Pain Visual Analog Scale;

Countries

China

Contacts

Public ContactShoushi Wang

Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital)

wangshoushi@uhrs.edu.cn+86 185 6185 6159

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026